Session » Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)
- 10:00AM-10:15AM
-
Abstract Number: 0873
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
- 10:15AM-10:30AM
-
Abstract Number: 0874
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
- 10:30AM-10:45AM
-
Abstract Number: 0875
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
- 10:45AM-11:00AM
-
Abstract Number: 0876
Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
- 11:00AM-11:15AM
-
Abstract Number: 0877
Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
- 11:15AM-11:30AM
-
Abstract Number: 0878
Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study